Market Overview:

The Europe hospital acquired disease testing market exhibited robust growth during 2015-2020. Looking forward, IMARC Group expects the market to continue its robust growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hospital-acquired diseases (HAD), or nosocomial infections, are illnesses caused by exposure to viral, bacterial and fungal pathogens during hospital visits. Some commonly known infections are catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).  The various tests used to diagnose these infections are complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, and urinalysis, cultures of the infected area, blood, urine and other body fluids. Other diagnostic tests, such as antimicrobial susceptibility testing (AST), are conducted for the testing of tuberculosis.

The increasing prevalence of hospital-acquired infections across Europe is one of the key factors driving the market. Furthermore, various technological advancements, such as the development of innovative diagnostic instruments and technologies, including flow cytometry, mass spectrometry and near-infrared spectroscopy, are providing a boost to the market growth. Additionally, the growing awareness regarding HADs and the available treatment options among patients, along with extensive research and development (R&D) in the field of medical sciences, are contributing to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the Europe hospital acquired disease testing market, along with forecasts at the regional and country level from 2021-2026. Our report has categorized the market based on indication.

Breakup by Indication:

• UTI (Urinary Tract Infection)
• SSI (Surgical Site Infection)
• Pneumonia
• Bloodstream Infections
• MRSA (Methicillin-Resistant Staphylococcus Aureus)
• Others
   

Breakup by Country:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Others
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Key Questions Answered in This Report:

• How has the Europe hospital acquired disease testing market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Europe hospital acquired disease testing market?
• What are the key regional markets?
• What is the breakup of the market based on the indication?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the Europe hospital acquired disease testing market and who are the key players?
• What is the degree of competition in the industry?